期刊
JOURNAL OF CONTROLLED RELEASE
卷 164, 期 2, 页码 156-169出版社
ELSEVIER
DOI: 10.1016/j.jconrel.2012.05.042
关键词
Cancer drug delivery; Nanomedicine; Translational; Nanocarriers
资金
- National Fund for Distinguished Young Scholars [50888001]
- Major Program of National Natural Science Foundation of China [21090352]
- National Natural Science Foundation [20974096]
- Program for Changjiang Scholars and Innovative Research Team in University of China
- U.S. Department of Defense [BC090502]
- Div Of Chem, Bioeng, Env, & Transp Sys
- Directorate For Engineering [1034530] Funding Source: National Science Foundation
Cancer drug delivery achieving high therapeutic efficacy and low side effects requires a nanocarrier to tightly retain the drug, efficiently reach the tumor, then quickly enter the tumor cells and release the drug. Furthermore, the nanocarrier intended for clinical applications should use materials safe as pharmaceutical excipients and its formulation (nanomedicine) should have good manufacture processes with scale-up ability. Thus, the challenge is to design safe, approvable, and easily scaled-up nanocarriers that simultaneously meet the two pairs of requirements of 'drug retention in circulation versus intracellular release' and 'stealthy in circulation versus sticky (cell-binding) in tumor' at the right places in order to deliver a cytosolic drug dose lethal to cancer cells with minimized side effects. Herein, we briefly review these elements aimed at promoting developments of translational nanocarriers. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据